#USA #New York #Lucid Diagnostics #Medicare #EsoGuard

Overview of Lucid Diagnostics' Progress

Lucid Diagnostics Inc., a prominent player in cancer prevention diagnostics and a subsidiary of PAVmed Inc., has recently shared significant updates regarding its business operations and financial performance for the third quarter of 2026. The company's focus remains on enhancing the accessibility and efficiency of its groundbreaking EsoGuard® test for esophageal cancer, following recent Medicare reimbursements that have opened new commercial avenues.

Key Developments

On November 12, 2026, Lucid announced that Medicare has officially begun reimbursing the EsoGuard Esophageal DNA Test nationwide, a pivotal moment for the company. Dr. Lishan Aklog, Chairman and CEO, emphasized the importance of this development, stating it is a major step forward in Lucid's mission to combat esophageal cancer. The company aims to leverage this change to accelerate growth and improve commercial performance.

Commercial Expansion

Since Medicare beneficiaries can now receive compensation for this critical test, Lucid has shifted its commercial strategy to capitalize on this newly opened market. Dr. Aklog indicated that this transformative change reduces the limitations previously faced due to external reimbursement issues. For Lucid, the main factors driving growth will now be the effectiveness of their commercial and operational strategies.

In October, just weeks into this new phase, Lucid achieved record testing volumes, performing over 1,800 EsoGuard tests, significantly contributing to revenue.

Financial Outcomes

In their Q3 results, Lucid reported $1.2 million in revenues directly linked to the EsoGuard test. Operating expenses totaled approximately $13.5 million, slightly elevated due to stock-based compensation. The GAAP net loss attributed to common stockholders stood at around $6.7 million.

Despite these challenges, a solid $15 million funding round completed after the quarter-end indicates a robust financial strategy to support future operations. This private placement is part of a broader effort to secure necessary capital for expanding operations and advancing research.

Looking Ahead

Moving forward, Lucid outlines its intention to aggressively pursue growth in the Medicare beneficiary segment, which represents a substantial portion of patients needing esophageal precancer screening. They have undertaken several initiatives, including active engagement with healthcare plans and launching programs in collaboration with the U.S. Department of Veterans Affairs, which are expected to enhance long-term revenue.

Notable Achievements

Recent achievements further bolster Lucid’s position, including:

• - Successful billing milestones with new codes for procedures associated with EsoGuard, facilitating easier integration into clinical practice.
• - Publication of a significant study confirming the efficacy of the EsoGuard test among a vast population, providing robust evidence in support of its use.
• - Recognition from the American Gastroenterological Association, which endorses EsoGuard as a viable alternative to traditional endoscopic methods.

These developments highlight Lucid Diagnostics' commitment to improving detection and prevention methods for esophageal cancer, primarily among at-risk populations. As they continue to scale operations and capitalize on new market opportunities, Lucid is poised to make significant strides in the field of medical diagnostics.

Conclusion

The third quarter of 2026 marks a turning point for Lucid Diagnostics, showcasing their resilience and potential for growth. As they navigate this new chapter, the focus on commercial expansion and operational efficacy will be critical to their long-term success in the competitive landscape of medical diagnostics.